Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: james who wrote (1369)	12/5/1997 1:40:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 4676

>>Do you mean current 2302 p2 formula is topical?<< No. It is i.v. infusion. But you give me something to consider in future. >>Polar/hydrophilic help skin penetration, since AS works intracellularly, would cell membrane be a problem, which is non-polar/hydrophobic? Would lipo/suger coating of AS help?<< Probably it will. Also, antisense bind tightly to protein and partially neutralize polarity. Phosphothionate are less polar than phosphate. mz p.s. Small correction: I-CAM iz ICAM-1.